patients had higher rates of panic attacks than those of the nonrespiratory subtype, indicating greater sensitivity to CO 2 . The characterization of PD subtypes through CO 2 challenge may be useful in elucidating the biological features, course, and response to treatment of PD. The lifetime risk of depression in those with multiple sclerosis (MS) is very high, with some estimates exceeding 50% (1). In initial trials of interferon beta-1b, there were several suicide attempts and 1 completed suicide, compared with no suicides in the placebo group (2). Since that time, there has been concern that interferon treatment can cause depressive symptoms, and the product monograph suggests that patients treated with interferon beta-1b be "informed that depression and suicidal ideation may be a side effect of treatment" (3). Some recent studies have not confirmed this association. The following case suggests a causal link between interferon beta-1a treatment of MS and major depressive disorder.
Depression in Multiple Sclerosis Associated With Interferon Beta-1a (Rebif)
Dear Editor:
The lifetime risk of depression in those with multiple sclerosis (MS) is very high, with some estimates exceeding 50% (1) . In initial trials of interferon beta-1b, there were several suicide attempts and 1 completed suicide, compared with no suicides in the placebo group (2) . Since that time, there has been concern that interferon treatment can cause depressive symptoms, and the product monograph suggests that patients treated with interferon beta-1b be "informed that depression and suicidal ideation may be a side effect of treatment" (3) . Some recent studies have not confirmed this association. The following case suggests a causal link between interferon beta-1a treatment of MS and major depressive disorder.
Case Report
A 42-year-old Caucasian woman diagnosed in March 2001 with clinically definite relapsing and remitting MS was started on interferon beta-1a therapy the same month. The Center for Epidemiological Studies Depression Rating Scale (CES-D) score (4, 5) , obtained prior to initiation of interferon beta-1a, was 4. A second rating, obtained in September 2001, was 28. The patient described a 5-month history of sustained depressed mood, crying spells, sleep disturbance (early morning awakening), hostility, amotivation, apathy, no libido, poor concentration and short-term memory, and a depressed cognitive shift (that is, feelings of hopelessness and guilt). Regarding psychiatric history, the patient had never seen a psychiatrist or mental health professional prior to the consultation in December 2001. However, she did acknowledge a remote history of bulimia nervosa in her teens. Medical history and family history were not contributory to her depression.The patient was started on citalopram in November 2001, and 6 weeks after initiation of the antidepressant she noticed a decrease in sadness and hostility. Her sleep also improved. A CES-D was repeated in December 2001 and her score was 23.
The 5 point reduction in CES-D scores was modest, but there was a significant clinical reduction in depressive symptomatology, and she was able to continue with interferon beta-1a treatment. It has been shown that patients with MS who have depression often discontinue therapy (6); this patient felt well enough to continue with her prescribed diseasemodifying therapy.
An analysis of depression data from the PRISMS clinical trial showed no evidence of increased depressive symptomatology associated with interferon beta 1a (the median change in CES-D score after 6 months of treatment was 0) (7). While the PRISMS trial provides evidence that depression must be a rare event during interferon treatment, clinicians should maintain an index of suspicion. If significant depressive symptoms arise, pharmacotherapeutic treatment appears to be an option. In our case, there was a beneficial response to selective serotonin reuptake inhibitor (SSRI) therapy (citalopram). Recent studies have shown that prophylactic treatment with paroxetine is an effective strategy to minimize depression induced by treatment with interferon alfa-2b for malignant melanoma (8) . It is also evident that swift detection and treatment can reduce the impact of major morbidity associated with MS.
